The epidemiology of nonalcoholic fatty liver disease: a global perspective
- PMID: 18956290
- DOI: 10.1055/s-0028-1091978
The epidemiology of nonalcoholic fatty liver disease: a global perspective
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease in the United States and worldwide. With obesity being an important risk factor universally, NAFLD is now receiving greater attention and is regarded as a public health issue. In addition, as a result of an aging population and the improving control of other major causes of chronic liver disease, such as hepatitis C and hepatitis B, the burden of NAFLD is expected to increase in years to come. Prevalence estimates of this disease vary widely across populations because of differences in methods for diagnosis and/or definition. New strategies for the prevention, diagnosis, and management will be required to alter the course of this disease.
Similar articles
-
Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic.Am J Med Sci. 2011 Jun;341(6):485-92. doi: 10.1097/MAJ.0b013e3182018598. Am J Med Sci. 2011. PMID: 21412139 Review.
-
Cryptogenic cirrhosis and NAFLD: are they related?Am J Gastroenterol. 2006 Mar;101(3):664-8. doi: 10.1111/j.1572-0241.2006.00478.x. Epub 2006 Feb 8. Am J Gastroenterol. 2006. PMID: 16464222
-
Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.Semin Liver Dis. 2007 Aug;27(3):312-8. doi: 10.1055/s-2007-985075. Semin Liver Dis. 2007. PMID: 17682977 Review.
-
Nonalcoholic fatty liver disease.Minerva Med. 2008 Dec;99(6):583-93. Minerva Med. 2008. PMID: 19034256 Review.
-
Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity.Circulation. 2004 Nov 2;110(18):e476-83. doi: 10.1161/01.CIR.0000140114.83145.59. Circulation. 2004. PMID: 15520332 No abstract available.
Cited by
-
Involvement of exercise-induced macrophage migration inhibitory factor in the prevention of fatty liver disease.J Endocrinol. 2013 Aug 29;218(3):339-48. doi: 10.1530/JOE-13-0135. Print 2013 Sep. J Endocrinol. 2013. PMID: 23823021 Free PMC article.
-
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.World J Hepatol. 2015 Feb 27;7(2):204-12. doi: 10.4254/wjh.v7.i2.204. World J Hepatol. 2015. PMID: 25729475 Free PMC article. Review.
-
An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus.J Diabetes Res. 2016;2016:2902351. doi: 10.1155/2016/2902351. Epub 2016 Jul 31. J Diabetes Res. 2016. PMID: 27547764 Free PMC article. Review.
-
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.J Gastroenterol. 2013 Apr;48(4):491-503. doi: 10.1007/s00535-012-0651-7. Epub 2012 Aug 14. J Gastroenterol. 2013. PMID: 22886508
-
Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease.Asian Pac J Trop Biomed. 2012 Sep;2(9):702-6. doi: 10.1016/S2221-1691(12)60213-5. Asian Pac J Trop Biomed. 2012. PMID: 23569998 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical